Anti-HIV Antibody 10-1074 Variants for Stability and Neutralization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HIV treatments lack effective therapeutic agents that can inhibit HIV infection and address the challenges posed by viral mutation and immunosuppression, despite the potential of broadly neutralizing antibodies in animal models.
Innovation Solution
Development of anti-HIV antibody variants with modified light and heavy chain variable regions to enhance biophysical characteristics, including specific amino acid substitutions, which improve stability and neutralization efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If broadly neutralizing antibodies are used to treat HIV infection, then neutralization efficacy is improved, but stability and resistance to aggregation are worsened
Solution Approach 1:
The patent applies parameter changes by systematically modifying amino acid residues at specific positions (Framework positions 1-4 and 7-9, and CDR positions 1-3) to optimize the balance between neutralization efficacy and stability. Through iterative mutagenesis and selection, antibody variants were generated with improved biophysical properties while maintaining or enhancing HIV neutralization capability.
Solution Approach 2:
The patent applies local quality by making targeted amino acid substitutions at specific local positions within the antibody variable regions rather than global modifications. This allows precise optimization of stability-critical regions (Framework) and binding-critical regions (CDR) independently, resolving the contradiction between stability and efficacy.
2Stability of the object's composition
If amino acid substitutions are made to improve stability, then stability is improved, but neutralization efficacy may be worsened
Solution Approach 1:
The patent distinguishes between Framework regions (positions 1-4 and 7-9) that primarily influence stability and CDR regions (positions 1-3) that primarily influence binding efficacy. By making targeted substitutions in Framework regions while preserving CDR integrity, the patent improves stability without compromising neutralization efficacy.
Solution Approach 2:
The patent employs iterative cycles of mutagenesis, expression, purification, and functional characterization to identify substitutions that improve stability while maintaining efficacy. This feedback-driven optimization allows selection of variants that achieve the desired balance between stability and neutralization capability.
3Stability of the object's composition
If antibody variants are developed to enhance biophysical characteristics, then stability and resistance to aggregation are improved, but device complexity and manufacturing complexity increase
Solution Approach 1:
The patent defines a finite set of amino acid substitutions at specific positions with demonstrated benefits for stability and aggregation resistance. This parameter-based approach simplifies manufacturing by providing clear guidelines for variant production, reducing the complexity of developing and characterizing numerous random mutants.
Data Source
AI summary
The present disclosure provides optimized broadly-neutralizing anti-HIV antibodies, having modified light chain variable regions and/or heavy chain variable regions leading to improved biophysical characteristics. The present disclosure also provides methods for producing these anti-HIV antibodies and methods of use thereof.